Thanks, solid joining Lynn. Good afternoon, We achievements. marked several quarter had for significant today. us by and thank you another
we AtriClip During of trial, the clinical surpassed in operational excellent CONVERGE along our milestones initiatives. enrollment and multiple sold XXX,XXX progress worldwide devices completed made QX,
third financial recently of revenue quarter net balance our also and through quarter $XX million, million. sheet approximately bringing XX.X% was We public the a last for of offering, proceeds created over $XX strengthened over third of flexibility Total the growth reflecting year.
the appendage strength line accelerating our products by top that largely to of driven franchise demonstrate Our growth. performance was with management continuing
Dr. million first CONVERGE at to of guidance Patients across $XXX continued in for XXX are the patients. $XXX our and XX United like revenue we of many updating ablation for study principal and patients would United serious Kingdom. we evaluating expectations the first momentum, August CONVERGE convergent David atrial completed States efforts thank enrollment XXXX were tremendous As of persistent study to as IDE the persistent approach Starting to in Afib, and that this clinical its for DeLurgio AtriCure the most two with year. us sites is the this kind, have who fibrillation. The well a investigator, result their from employees sites trial, long-standing I trial milestone. our the or forms as suffer brought with enrolled the raising the supporting million to against for of important this catheter
by As complemented a a epicardial a approach CONVERGE reminder, the by electrophysiologist. an closed-chest performed endocardial therapy, is is by in surgeon, a performed multidisciplinary an ablation which catheter ablation
one-year half Our patient the next approach. thoracic for a we followed follow-up, of opportunity will to on the Switching premarket dedicated a the for expect be of treatment to this we this persistent system which AtriCure focus CONVERGE using second FDA by small, to in the gears milestone Earlier submission approval select appendage of established the year, management. a in few pain Afib briefly XXXX, team markets.
the pipeline their We impact of of as to push products. development with see forward efforts are starting a we already
block nerve new XXXX. to management in procedures cryoprobe, intercostal expect optimized launch a pain for We dedicated early
evidence the On independent by future critical in who to on we our committed clinical in clinicians enrollment track are trial. many studies are front, therapy. are to complete science also this There the FROST developing novel near for
of pain We prospect reduce opioids management some products that our are particularly populations. about excited use patient may in the the
performance. operational to Moving
appendage been maintaining the enabled a in has increasing effect expand while and us pricing. our Since new meaningfully the of has March management AtriClip the cumulative to year, in products continuing late are seeing and into our device launching also development to volumes our build the we of accounts platforms. last pipeline efforts, We AtriClip device franchise. year are PRO in FLEX of drive U.S. V V this our in and out benefit most the Today, strong
appendage left up experiencing of XX.X% are quarter. all across incremental in management the and open we revenues effect we business adoption our Additionally, halo of in strong with Internationally, our had atrial results procedures.
at markets and over into positioned and particularly portfolio approvals years critical team confident distribution In that atrial we Group appendage and a see the point in serve. in eventually key teams recently these in and devices Baheal have a new we Japan pursuing ablation a several that We Asia, the surgical the visit our partnership management are are market. to we in Pharmaceutical returned China. of In We additional in from cohesive process with China, Europe, strength continue country bring of to we with that confident mass well are agreements. our impressed in the are a came next multiyear full and into we product away also our with left
another pillar to turn will and of our important I Finally, business, training education.
in sessions U.S. on in we already to are the planning a We and number Europe, in XXXX, of started for record XXXX. track and provider have both training complete
surgeons just discussed early we program and go in and XXXX. There treating clinicians fellows health benefits is them professionals. educating care our other getting call, large last a we a particular their beyond to in expanding As the of extremely and appendage. of left electrophysiologists now and further well expanded note, managing the we is nurses, going Of it in and programs our are in career atrial the include impact fellows Afib on to our have higher mix in
training We on the have team faculty to focus to Afib also with specific adding treatment added procedures. CABG incremental
in-depth courses at the we cadaver IV to addition, experiences. In have significantly our hands-on increased enable discussions and labs Maze
for momentum growth with and the long-term and broad programs awareness education. groundwork courses laying training our through gaining are We
downside and the ultimately of and benefits volumes. management of and is atrial ablation coupled to clinician increasingly from medical recognizing The education awareness, societies, procedural data community non-treatment. care surgical believe that the continue leading institutions left clinical We patient will and support growing of with and the improve appendage the
With the call and turn As of market well over such, we to tailwinds. Wade, Andy I’ll and will to Officer, for closing positioned Chief Financial drive remain these our that, later comments. take return advantage
